CD274 and neoplasm: The incidence of DNA mismatch repair-deficient, microsatellite-unstable tumours is of particular clinical relevance since it has been shown that DNA mismatch repair-deficient tumours are significantly more responsive to immune checkpoint blockade, particularly using antibodies directed against the immune checkpoint Programmed cell Death protein 1 (PD-1) or Programmed Death-Ligand 1 (PD-L1),1 than DNA mismatch repair-proficient tumours.